文献速递血管炎

超短程糖皮质激素联合托珠单抗治疗巨细胞动脉炎:影像学在前瞻性观察性研究中的作用

Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该前瞻性观察性研究纳入18例活动性大血管型巨细胞动脉炎患者,给予静脉甲泼尼龙500 mg/日连用3天,第4天起每周皮下注射托珠单抗至第52周;第24周和第52周PET血管活动评分(PETVAS)较基线显著降低,无复发生存比例分别为56%和47%,第24周和第52周均无新发主动脉扩张,但4例基线已有主动脉扩张者第52周主动脉直径显著增加(≥5 mm)。

要点

  • 超短程糖皮质激素后托珠单抗单药治疗可控制巨细胞动脉炎临床症状并减轻血管炎症。
  • 第24周和第52周PETVAS较基线平均降低-8.6(95%CI -11.5至-5.7)和-10.4(95%CI -13.6至-7.2)。
  • 第24周和第52周无复发生存比例分别为10/18(56%,95%CI 31-78)和8/17(47%,95%CI 23-72)。

核心结论

  • 超短程糖皮质激素后托珠单抗单药治疗可控制巨细胞动脉炎的临床症状并减轻血管炎症。

研究设计与样本

  • 前瞻性观察性研究,纳入18例活动性大血管型巨细胞动脉炎患者(72%女性,平均年龄68.5岁)。
  • 所有患者接受静脉甲泼尼龙500 mg/日连用3天,第4天起每周皮下注射托珠单抗至第52周。
  • 所有患者在基线及第24周和第52周行PET/CT检查。

主要发现

  • 与基线相比,第24周和第52周PETVAS显著降低,平均(95%CI)降低分别为-8.6(-11.5至-5.7)和-10.4(-13.6至-7.2),P=0.001和0.002。
  • 第24周和第52周无复发生存比例分别为10/18(56%,95%CI 31-78)和8/17(47%,95%CI 23-72)。
  • 第24周和第52周均无患者出现新发主动脉扩张。
  • 4例基线已有主动脉扩张的患者在第52周主动脉直径显著增加(≥5 mm)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the impact of tocilizumab (TCZ) monotherapy after ultra-short-pulse glucocorticoids (GCs) on clinical manifestations, and vessel inflammation and damage in large vessel-GCA (LV-GCA). METHODS: In this prospective observational study, we enrolled patients with active LV-GCA. All patients received 500 mg per day i.v. methylprednisolone for three consecutive days and weekly s.c. TCZ injections from day 4 until week 52. PET/CT was performed on all patients at baseline and at weeks 24 and 52. The primary end points were the reduction in the PET vascular activity score (PETVAS) at weeks 24 and 52 compared with baseline, and the proportion of patients with relapse-free remission at weeks 24 and 52. The secondary end point was the proportion of patients with new aortic dilation at weeks 24 and 52. RESULTS: A total of 18 patients were included (72% female, mean age 68.5 years). Compared with the baseline value, a significant reduction in the PETVAS was observed at weeks 24 and 52, mean (95% CI) reductions -8.6 (-11.5 to -5.7) and -10.4 (-13.6 to -7.2), P = 0.001 and 0.002, respectively. The proportion of patients with relapse-free remission at weeks 24 and 52 was 10/18 (56%, 95% CI 31-78) and 8/17 (47%, 95% CI 23-72), respectively. At weeks 24 and 52, no patient had shown new aortic dilation. However, 4 patients who had shown aortic dilation at baseline showed a significant increase in aortic diameter (≥5 mm) at week 52. CONCLUSION: TCZ monotherapy after ultra-short-pulse GCs controlled the clinical symptoms of GCA and reduced vascular inflammation. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT05394909.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Muratore F, Marvisi C, Cassone G, et al. Treatment of giant cell arteritis with ultra-short glucocorticoids and tocilizumab: the role of imaging in a prospective observational study. Rheumatology (Oxford). 2024. PMID: 37195423. doi:10.1093/rheumatology/kead215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。